Compare Ginkgo Bioworks Holdings Inc (DNA) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Southwest Airlines Co — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.87 (market cap $772.39M), while Southwest Airlines Co trades at $41.41 (market cap $20.41B). The key difference: Southwest Airlines Co is far larger — about 26.4× Ginkgo Bioworks Holdings Inc's market cap, and Southwest Airlines Co pays a 1.73% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Southwest Airlines Co for 65 Days on average.
| DNA | LUV | |
|---|---|---|
Market Cap | $772.39M | $20.41B |
Volume | 6,453,273 | 4,706,365 |
Sector | Health | Industrials |
52-Week High | $15.83 | $54.80 |
52-Week Low | $5.48 | $29.67 |
Typical Hold Time | 7 Days | 65 Days |
Enterprise Value | $874.34M | $23.51B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.
The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.
Southwest Airlines (LUV) trades at $41.36, down 2.57% with a bearish technical signal. The company shows mixed fundamentals with a P/E of 26.08 and net margin of 2.78%, while recent earnings beat expectations in Q2 2026. Cash flow trends improved significantly in 2026 projections. Analyst consensus is divided with 42% buy ratings and a $49.61 price target representing 20% upside potential.
LUV's transformation initiatives show promise with projected $2 billion EBIT from new fare structures, though high fuel costs and competitive pressures remain risks. The stock offers value with P/S of 0.73 and strong revenue growth outlook, but requires monitoring of Q3 2026 earnings due October 22 for confirmation of the turnaround trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
